Retrospective Analysis Of Gestational Trophoblastic Neoplasia: Single Center Experience

This study aims to analyze the clinicopathologic characteristics and treatment outcomes of our patients with gestational trophoblastic neoplasia (GTN) and to present our real-life experience. A total of 32 patients with GTN diagnosed according to the FIGO 2002 criteria followed in Zekai Tahir Burak Women's Health Training and Research Hospital between 2011-2018 were included. Demographic features, treatment outcomes, and survival were analyzed retrospectively. The median follow up time was 32.1 (3.3-76.9) months. Of the 32 patients, 27 (84.4%) were defined as low-risk GTN (risk score = 7) according to the FIGO risk score. Seventeen (62.9%) patients with low-risk GTN achieved complete remission (CR) with single agent MTX. CR rate was 60% (12/20) in patients receiving weekly MTX and 71.4% (5/7) in MTX-FA eight-day regimen (p= 0.590). Of the 9 MTX resistant patients, 8 (88.8%) achieved CR with second-line Actinomycin D (ActD). Three (60%) out of the five high-risk GTN patients acquired CR with first-line EMA-CO (etoposide, MTX, plus ActD alternating with cyclophosphamide and vincristine). In the follow-up period one patient (3.1%) had recurrent disease. By the data cut off date, all of the patients were alive and CR could not be achieved in one (3.1%) patient. All patients with low-risk GM achieved CR with sequential therapies ultimately. Therefore, single agent MTX is a reasonable option in the initial treatment of low-risk GTN. Moreover, Actinomycin D is highly effective in patients with low-risk GTN who are resistant to MTX.WoSScopu

Mucoepidermoid Carcinoma Of Uterine Cervix: A Distinct Pathological And Clinical Entity

Mucoepidermoid carcinoma of uterine cervix is a rare tumor that has some individual features. Defining risk factors after surgery shape the postoperative treatment modality on cervical cancer patients. Although there is not a well-known strategy for the postoperative follow-up of mucoepidermoid carcinoma, the aggressive behaviour of this tumor makes the gynecological oncologists choose liberal therapies on these patients

May Lymphadenectomy Be Omitted in Granulosa Cell Tumors of the Ovary?

Granulosa cell tumors (GCTs) of the ovary are rare tumors and they are generally detected in early stages with a favorable prognosis. However, the controversies over the extend of surgery are still judging the surgical management. We retrospectively evaluated demographic and clinical variables of granulosa cell tumors of the ovary with probable prognostic factors to identify the clinicopathological features. Women with adult type granulosa cell tumor pathology result between March 2007 and April 2013 were evaluated retrospectively using computerized database of the institution. Age, stage, menopausal status, parity, clinical presentation, surgical procedures, histopathologic results, preoperative tumor markers, tumor diameter and laterality were the reviewed parameters. Patients were staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging system for ovarian tumors that was revised in 2014. A total of 40 patients were retrospectively evaluated. We further categorized patients as stage 1A and more advanced stage disease. Twenty-seven patients (67.5%) were within Stage 1A disease and 13 (32.5%) patients had more advanced stage of disease. Only one patient had retroperitoneal lymph node involvement and recurred 2 years after the completion of the chemotherapy, and died of disease after 2 years from recurrence. Since the risk of unintended complications and morbidity, which is related with lymph node dissection, the rare incidence of lymph node involvement should be kept on mind. So that omitting lymphadenectomy could be an option for GCTs if a low mitotic index ( [Med-Science 2016; 5(2.000): 496-504